Étiquette : douleur

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand, Graham Gulbransen et al, 2020

Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand Graham Gulbransen, MBChB, FAChAM, FRNZCGP1*, William Xu2, Bruce Arroll, MBChB, PhD, FRNZCG BJGP Open, 2020, 1-8 DOI : 10.3399/bjgpopen20X101010   Abstract Background : Cannabidiol (CBD) is the non- euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear. Aim : To review the changes in self- reported quality of life measurements, drug tolerability, and dose- dependent relationships in patients prescribed CBD oil for various conditions at a single institution. Design & setting : An [...]

Lire la suite

Cancer, Cannabis, and the Search for Relief, Marcin Chwistek, 2019

Cancer, Cannabis, and the Search for Relief Marcin Chwistek JNCCN—Journal of the National Comprehensive Cancer Network, 2019, Volume 17, Issue 9, 1142-1144. doi : 10.6004/jnccn.2019.7347   “How about medical marijuana?” is a common and often challenging question in oncology clinics today. It is easy to see why. Answering the question is fraught with clinical, legal, and administrative uncertainties. We all want to give patients the best advice, but not much about medical cannabis seems straightforward today. Whatever answer we provide can feel unsatisfactory to patients or ourselves. Answering clinical questions through high-quality research will take many years. And significant political power will be needed to [...]

Lire la suite

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers, Johannes G. Ramaekers et al., 2020,

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers Johannes G. Ramaekers, Nadia Hutten, Natasha L. Mason, Patrick Dolder1, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding and Kim P.C. Kuypers Journal of Psychopharmacology, 2020, 1–8. doi : 10.1177/026988112094093   Abstract Background : Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim : The present [...]

Lire la suite

Cannabis Misconceptions Still Common Among MS Clinicians, Nancy Melville, Medscape.com, 2020

Cannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1   Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]

Lire la suite

Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado, Amalie K. Kropp Lopez et al., 2020

Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado Amalie K. Kropp Lopez, Stephanie D. Nichols, Daniel Y. Chung, Daniel E. Kaufman, Kenneth L. McCall  and Brian J. Piper International Journal of Environmental Research and Public Health, 2020, 17, 3251 doi : 10.3390/ijerph17093251   Abstract : There have been dynamic changes in prescription opioid use in the US but the state level policy factors contributing to these are incompletely understood. We examined the association between the legalization of recreational marijuana and prescription opioid distribution in Colorado. Utah and Maryland, two states that had not legalized recreational marijuana, were selected for comparison. Prescription data reported to [...]

Lire la suite

Effet d’entourage contre douleur neuropathique, PrincipesActifs.org, 22 Mai 2020

Effet d’entourage contre douleur neuropathique Publié le 22 Mai 2020 https://www.principesactifs.org/effet-dentourage-contre-douleur-neuropathique/     Cette huile de cannabidiol est efficace contre la douleur neuropathique chronique, conclut cette étude pré-clinique de l’University of New Mexico (UNM). L’étude présentée dans la revue Life suggère que l’huile permet de diviser par 10 la sensibilité à la douleur mécanique et pendant plusieurs heures. Ici chez la souris modèle de douleur neuropathique postopératoire chronique. Ces données présentées dans la revue Life illustrent ce que les experts nomment l’effet d’entourage ou l’action synergique de différents composés du cannabis qui apporte cet effet thérapeutique. Dans cette expérience, il s’agit d’une huile de cannabis contenant [...]

Lire la suite

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity, Marie Fitzgibbon et al., 2016

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn,  Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095   Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]

Lire la suite

What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms ? A comprehensive review, Gabrielle Campbell, 2018

What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms ? A comprehensive review Gabrielle Campbell, Wayne Hall and Suzanne Nielsen International Review of Psychiatry, 2018, 1-16. Doi : 10.1080/09540261.2018.1509842   ABSTRACT Pre-clinical research supports that cannabinoids reduce opioid dose requirements, but few studies have tested this in humans. This review evaluates ecological and epidemiological studies that have been cited as evidence that medical cannabis use may reduce opioid use and opioidrelated harms. Medline and Embase were searched for relevant articles. Data were extracted on study setting, analyses approach, covariates, and outcomes. Eleven ecological and 14 epidemiological [...]

Lire la suite

Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients, Phillip Olla et al., 2019

Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients Phillip Olla, Nicholas Rykulski, Jessica L. Hurtubise, Stephen Bartol, Rachel Foote, Laura Cutler, Kaitlyn Abeare, Nora McVinnie, Alana G. Sabelli, Maurissa Hastings, and Laszlo A. Erdodi Applied Neuropsychology : Adult, 2019, 1-11. Doi : 10.1080/23279095.2019.1681424   ABSTRACT This observational study examined the acute cognitive effects of cannabis. We hypothesized that cognitive performance would be negatively affected by acute cannabis intoxication. Twenty-two medical cannabis patients from Southwestern Ontario completed the study. The majority (n¼13) were male. Mean age was 36.0 years, and mean level of education was 13.7 years. Participants were administered the same brief neurocognitive battery three times during [...]

Lire la suite

Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction, Selena N. Clem et al., 2019

Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction Selena N. Clem, Teresa L. Bigand, Marian Wilson Pain Management Nursing, 2019, 1-5. Doi : 10.1016/j.pmn.2019.06.009   a b s t r a c t Background : Cannabis has been linked to reduced opioid use, although reasons for cannabis use among adults prescribed opioids are unclear. Aims : The purpose of this study was to determine whether motivations for cannabis use differ between adults prescribed opioids for persistent pain versus those receiving opioids as medication-assisted treatment for opioid use disorder. Design : A cross-sectional survey design was used. Participants : Adults prescribed opioids for persistent pain (n [...]

Lire la suite